| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2016-10-04 | Amgen (USA - CA) Nuevolution (Denmark) | R&D licensing commercialisation |
Cancer - Oncology - Neurological diseases | Licensing agreement | ||
| 2016-10-04 | Apeiron Biologics (Austria) EUSA Pharma (UK) | Isqette® (APN311 - dinutuximab beta) | neuroblastoma | commercialisation | Rare diseases - Cancer - Oncology | Commercialisation agreement |
| 2016-10-03 | AstraZeneca (UK) Allergan (Ireland) | MEDI2070 | Crohn disease, ulcerative colitis | licensing |
Autoimmune diseases - Inflammatory diseases - Digestive diseases | Licensing agreement |
| 2016-10-03 | Abreos Biosciences (USA - CA) Institut Paoli-Calmettes (France) | collaboration etablishment of a new subsidiary in the EU |
Cancer - Oncology | Establishment of a new subsidiary in the EU | ||
| 2016-10-03 | Cambrex (USA - NJ) | manufacturing and R&D site in Paullo (MI), Italy | opening of new premises | Technology - Services | Opening of new premises | |
| 2016-09-29 | Sarepta Therapeutics (USA - MA) Catabasis Pharmaceuticals (USA - MA) | exon skipping treatment and oral NF-kB inhibition treatment, edasalonexent (CAT-1004) | Duchenne muscular dystrophy | R&D |
Rare diseases - Genetic diseases - Neuromuscular diseases | R&D agreement |
| 2016-09-29 | Bluebird bio (USA - MA) Medigene (Germany) | T cell receptor (TCR) immunotherapies against four targets | R&D licensing |
R&D agreement | ||
| 2016-09-29 | Boehringer Ingelheim (Germany) Sarah Cannon Research Institute (SCRI) (USA - CO) | BI 754091 and BI 754111 | non-small cell lung cancer (NSCLC) | clinical research |
Cancer - Oncology | Clinical research agreement |
| 2016-09-29 | Genentech, a member of Roche Group (USA - CA - Switzerland) Hanmi Pharmaceutical (Republic of Korea) | HM95573 | licensing |
Cancer - Oncology | Licensing agreement | |
| 2016-09-29 | Amgen (USA - CA) Arrowhead Pharmaceuticals (USA - CA) | RNA interference (RNAi) therapies for cardiovascular disease including RNAi ARC-LPA program | licensing development commercialisation |
Cardiovascular diseases | Licensing agreement | |
| 2016-09-28 | Chugai Pharmaceutical (Japan) Maruho (Japan) | nemolizumab (CIM331) | skin diseases | licensing |
Dermatological diseases | Licensing agreement |
| 2016-09-28 | GSK (UK) Oncodesign (France) | François Hyafil Research Centre | R&D premises acquisition | Cancer - Oncology | Plant acquisition | |
| 2016-09-28 | Medday (France) | nomination |
CNS diseases - Neurological diseases - Neurodegenerative diseases | Nomination | ||
| 2016-09-28 | Anavex Life Sciences (USA - NY) Biogen (USA - MA) | ANAVEX2-73 (tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride) | collaboration materiel transfert agreement |
Neurological diseases - CNS diseases | Collaboration agreement | |
| 2016-09-28 | Poietis (France) L'Oréal (France) | bioprinting of hair | collaboration | Technology - Services | Collaboration agreement | |
| 2016-09-27 | Momenta Pharmaceuticals (USA - MA) Shire (UK - USA) | M923, a biosimilar version of Humira® (adalimumab) | licensing |
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases - Dermatological diseases | Termination of the agreement | |
| 2016-09-27 | Coherus Biosciences (USA - CA) Baxalta (USA - IL), now part of Shire (UK - USA) | CHS-0214 (investigational etanercept biosimilar) | development commercialisation |
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases - Dermatological diseases | Termination of the agreement | |
| 2016-09-27 | Gilead Sciences (USA - CA) World Health Organization | visceral leishmaniasis | collaboration |
Parasitic diseases | Collaboration agreement | |
| 2016-09-27 | Nektar Therapeutics (USA - CA) BMS (USA - NY) | Opdivo® (nivolumab) and NKTR-214 | melanoma, kidney cancer, colorectal cancer, bladder cancer, non-small cell lung cancer | clinical research |
Cancer - Oncology | Clinical research agreement |
| 2016-09-26 | Swedish Orphan Biovitrum - SOBI (Sweden) | nomination |
Nomination |
